News - Appointments

Lysando AG, which is developing technology to fight microbial infections, has appointed Leonhard Stärk to a new ethics committee which will guide it on the introduction of a product for gonorrhoea. He will be joined on the committee by Karl Liese.

Macrophage Pharma Ltd has appointed Søren Bregenholt as chief executive officer to guide development of its small molecule drugs for cancer that work by inducing transcriptional reprofiling of macrophages.

Hookipa Pharma Inc has appointed Christine Baker as chief business officer and Roman Necina as chief technology officer to lead the next phase of the company’s strategic development.

The Menarini Pharmaceutical Group, with headquarters in Florence, Italy, has appointed Elcin Barker Ergun as group chief executive.

Jane Osbourn, who contributed to the development of phage display technology, has been appointed chair of the board of Mogrify Ltd, which has developed a proprietary direct cellular conversion technology.

Belgium-based iTeos Therapeutics SA, which is developing therapies targeting the tumour microenvironment, has appointed Gordon Freeman as chair of its scientific advisory board to advance the company’s preclinical and clinical assets.

Christian Jung has joined the Dementia Discovery Fund as partner to expand its investment portfolio in Europe. The fund supports companies with novel therapeutics and platforms for the treatment of dementia.

Shakti Narayan has been appointed chief executive officer and a member of the board of directors at Accent Therapeutics Inc which is developing oncology-focused small molecule drugs in the field of RNA modification.

Tania Dimitrova, an experienced investor and business executive, has been appointed chief business officer at Artios Pharma Ltd as the company expands its presence in the US. Artios is developing cancer treatments based on DNA repair technology.

Mats Blom has become chief financial officer at the Dutch biotech NorthSea Therapeutics BV which is developing treatments for metabolic and fibrotic diseases including nonalcoholic steatohepatitis (NASH).